MGV vs XBI
Vanguard Mega Cap Value ETF vs SPDR S&P Biotech ETF
- • MGV has the lower expense ratio at 0.05% vs 0.35% for XBI.
- • MGV pays a higher dividend yield (1.96%).
Side-by-side metrics
| Metric | MGV | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.05% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.96% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $12.14B | $8.30B |
YTD return | 9.67% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.70 | 1.09 |
P/E ratio | 22.59 | — |
Last price | $152.65 | $133.66 |
Inception | — | — |
Issuer | Vanguard | State Street |
MGV top holdings
| JPM | JPMorgan Chase & Co | 3.86% |
| XOM | Exxon Mobil Corp | 3.69% |
| BRK-B | Berkshire Hathaway Inc Class B | 3.43% |
| JNJ | Johnson & Johnson | 3.08% |
| WMT | Walmart Inc | 2.84% |
| COST | Costco Wholesale Corp | 2.31% |
| CVX | Chevron Corp | 2.05% |
| ABBV | AbbVie Inc | 2.01% |
| MU | Micron Technology Inc | 1.98% |
| PG | Procter & Gamble Co | 1.75% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About MGV
MGV (Vanguard Mega Cap Value ETF) is Mega-cap US value stocks. Managed by Vanguard, the fund carries $12.1B in assets under management, an expense ratio of 0.05%, a dividend yield of 1.96%. Its largest holding is JPMorgan Chase & Co (JPM), which represents 3.9% of the portfolio. Real Estate is the fund's largest sector exposure at 1.2%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.